List of GLP-1 Medications: Every FDA-Approved Drug in 2026

As of 2026, nine GLP-1 brand names are FDA-approved and on sale in the United States: Wegovy, Zepbound, Foundayo, Saxenda, Ozempic, Rybelsus, Mounjaro, Trulicity, and Victoza. A generic version of Saxenda launched on August 28, 2025, and an authorized generic of Victoza is also listed as available [11, 12]. Two older exenatide products, Byetta and Bydureon BCise, were discontinued in October 2024, and one pending combination, CagriSema, is still under FDA review [11, 13].

Every product in this class carries a boxed warning about the risk of thyroid C-cell tumors, and each is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1, 2, 4, 5, 6, 7, 8, 9]. Two entries are not classic GLP-1 receptor agonists: tirzepatide (Zepbound and Mounjaro) acts on both the GIP receptor and the GLP-1 receptor [4, 5], and orforglipron (Foundayo) is a small-molecule, non-peptide oral GLP-1 receptor agonist ^[10]. The Wegovy, Zepbound, Foundayo, and Saxenda labels state that using the product together with another GLP-1 receptor agonist is not recommended [2, 4, 6, 8].

Product	Active ingredient	Form	FDA-approved uses
Wegovy / Wegovy HD	semaglutide	weekly injection	weight loss (adults and children 12+), cardiovascular risk, MASH [2]
Wegovy tablets	semaglutide	daily pill	weight loss and cardiovascular risk in adults [2]
Zepbound	tirzepatide	weekly injection	weight loss, obstructive sleep apnea [4]
Foundayo	orforglipron	daily pill	weight loss in adults [6, 10]
Saxenda (and generic)	liraglutide	daily injection	weight loss (adults and children 12+) [8, 12]
Ozempic	semaglutide	weekly injection	type 2 diabetes, cardiovascular risk, chronic kidney disease [1]
Ozempic tablets / Rybelsus	semaglutide	daily pill	type 2 diabetes, cardiovascular risk [3]
Mounjaro	tirzepatide	weekly injection	type 2 diabetes (adults and children 10+), cardiovascular risk [5]
Trulicity	dulaglutide	weekly injection	type 2 diabetes (adults and children 10+), cardiovascular risk [7]
Victoza (and authorized generic)	liraglutide	daily injection	type 2 diabetes (adults and children 10+), cardiovascular risk [9, 11]

What is Wegovy approved for?

The Wegovy injection label lists four uses: long-term weight reduction in adults and pediatric patients 12 and older with obesity; long-term weight reduction in adults with overweight plus at least one weight-related comorbid condition; reducing the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; and treating noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults, an indication approved under accelerated approval ^[2].

The label’s dosing schedule starts at 0.25 mg once weekly for 4 weeks and titrates every 4 weeks. The usual maintenance dosage is 2.4 mg once weekly, with 1.7 mg as an alternative. The 7.2 mg dose (Wegovy HD) is only for patients who have tolerated 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated ^[2]. Pens come in 0.25, 0.5, 1, 1.7, 2.4, and 7.2 mg single-dose strengths, plus a 9.6 mg/3 mL FlexTouch multi-dose pen that delivers four 2.4 mg doses ^[2].

Wegovy tablets come in 1.5, 4, 9, and 25 mg strengths. The label starts patients at 1.5 mg daily for 30 days and titrates every 30 days to a maintenance dosage of 25 mg daily. Tablets are taken on an empty stomach with up to 4 ounces of water, followed by a 30-minute wait before food, drinks, or other oral medicines. If the 25 mg dose is not tolerated, the label points to switching to the 1.7 mg injection ^[2]. The label shows indication changes in 08/2025 and 12/2025, a dosage change in 03/2026, and removal of the suicidal ideation warning in 01/2026 ^[2].

What is Zepbound approved for?

Zepbound is approved for long-term weight reduction in adults with obesity, or overweight with at least one weight-related comorbid condition, and for treating moderate to severe obstructive sleep apnea in adults with obesity ^[4].

The label starts patients at 2.5 mg injected once weekly for 4 weeks, then increases in 2.5 mg steps at least 4 weeks apart. Maintenance dosages are 5, 10, or 15 mg weekly for weight reduction, and 10 or 15 mg weekly for sleep apnea, with a maximum of 15 mg ^[4]. It comes as single-dose pens or vials from 2.5 to 15 mg, and as multi-dose vials or KwikPens that each hold four doses ^[4]. Tirzepatide’s initial US approval was 2022. The Zepbound label was revised in 8/2026; its Recent Major Changes list includes a diabetic retinopathy section change dated 08/2026 and removal of the suicidal ideation warning in 02/2026 ^[4].

What is orforglipron, the newest approval?

Foundayo (orforglipron) was FDA-approved on April 1, 2026 for adults with obesity, or overweight with at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity ^[10]. LillyDirect began shipping prescriptions on April 6, 2026, followed by retail pharmacies and telehealth providers ^[10].

The label describes a once-daily tablet taken with or without food and no water restrictions. Strengths are 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg, with dose increases at least 30 days apart and a maximum of 17.2 mg daily. The maximum is capped at 9 mg daily when used with a strong CYP3A4 inhibitor, and the label states it is not recommended in severe hepatic impairment ^[6].

In the ATTAIN-1 trial, 3,127 participants were randomized over 72 weeks. People taking the highest dose who stayed on treatment lost an average of 27.3 lb (12.4%) versus 2.2 lb (0.9%) on placebo; counting all participants regardless of completion, weight loss was 25 lb (11.1%) versus 5.3 lb (2.1%) ^[10]. Lilly’s announcement lists pricing of as little as $25 per month with commercial coverage and a savings card, self-pay starting at $149 per month for the lowest dose, and $50 per month for eligible Medicare Part D enrollees beginning as soon as July 1, 2026 ^[10]. It is not known whether Foundayo is safe or effective in children. Orforglipron was discovered by Chugai and licensed by Lilly in 2018 ^[10].

What about Saxenda and its generic?

Saxenda is a once-daily injection approved for long-term weight reduction in adults and pediatric patients 12 and older with body weight over 60 kg and obesity, and in adults with overweight plus at least one weight-related comorbid condition. Liraglutide’s initial US approval was 2010 ^[8].

The label starts at 0.6 mg daily for one week and increases at weekly intervals, reaching 3 mg from week 5. Pediatric patients who do not tolerate 3 mg may be reduced to 2.4 mg daily. For adults, the label says to evaluate weight change at 16 weeks and discontinue if less than 4% of baseline body weight has been lost ^[8].

Teva’s generic liraglutide injection, a copy of Saxenda, was FDA-approved and launched on August 28, 2025. Teva described it as the first generic GLP-1 indicated for weight loss. Saxenda had annual sales of $165 million as of June 2025 ^[12].

What is Ozempic approved for?

Ozempic injection is approved to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The label was revised in 05/2026 ^[1].

The label starts at 0.25 mg once weekly, moves to 0.5 mg after 4 weeks, then to 1 mg and 2 mg at 4-week minimums if more glycemic control is needed. It comes in multi-dose pens and in single-dose prefilled syringes at 0.25, 0.5, and 1 mg; the syringe strengths carry an FDA approval date of May 5, 2026 [1, 14]. Ozempic’s original approval was December 5, 2017 ^[14].

Rybelsus (3, 7, and 14 mg tablets) and Ozempic tablets (1.5, 4, and 9 mg) share one prescribing information. The label states they are not substitutable on a mg-to-mg basis and includes switching instructions between them and from Ozempic injection. The Ozempic tablet strengths carry an approval date of December 9, 2024 [3, 14]. For Ozempic tablets, the label starts at 1.5 mg daily for 30 days (a dose the label says is not effective for glycemic control), moves to 4 mg for days 31 to 60, and increases to 9 mg if more control is needed, with the same empty-stomach, 4-ounce water, and 30-minute wait rules as Wegovy tablets ^[3].

Is Mounjaro approved for children?

Yes. Mounjaro is approved to improve glycemic control in adults and pediatric patients 10 and older with type 2 diabetes (a label change dated 12/2025), and to reduce major cardiovascular events in adults with type 2 diabetes at high risk (a label change dated 08/2026) ^[5]. The label starts at 2.5 mg once weekly and increases in 2.5 mg steps, with a maximum of 15 mg in adults and 10 mg in pediatric patients [5, 19].

The pediatric approval rests on SURPASS-PEDS, which studied 99 patients aged 10 and older already on metformin, basal insulin, or both, randomized to tirzepatide 5 mg, 10 mg, or placebo for 30 weeks. A1c fell by a mean of 2% from baseline pooled across doses, a difference of -1.8% versus placebo. The Pediatric Endocrine Society report is dated February 24, 2026 and notes that side effects were consistent with adults, though vomiting, abdominal pain, and hypoglycemia rates were higher in children ^[19].

Are Trulicity and Victoza still available?

Yes. Trulicity (dulaglutide), initially approved in 2014, is approved for glycemic control in adults and pediatric patients 10 and older with type 2 diabetes and for reducing major cardiovascular events in adults with established cardiovascular disease or multiple risk factors. It comes in 0.75, 1.5, 3, and 4.5 mg weekly single-dose pens, with a pediatric maximum of 1.5 mg. The label was revised in 3/2026 ^[7].

Victoza (liraglutide), initially approved in 2010, is approved for glycemic control in adults and pediatric patients 10 and older with type 2 diabetes and for reducing major cardiovascular events in adults with established cardiovascular disease. It is dosed at 0.6, 1.2, or 1.8 mg daily, and the label was revised in 10/2025 ^[9]. A UnitedHealthcare notice lists the liraglutide (Victoza) authorized generic among GLP-1 products currently available for diabetes ^[11].

Which GLP-1 drugs have been discontinued?

AstraZeneca notified the FDA that it discontinued Byetta on October 25, 2024 and Bydureon BCise on October 28, 2024 ^[11]. A UnitedHealthcare notice dated December 19, 2024 lists Mounjaro, Ozempic, Rybelsus, Trulicity, and liraglutide as preferred covered alternatives for its commercial plans ^[11].

Is CagriSema approved yet?

No. As of a Drugs.com status page updated February 23, 2026, CagriSema is not FDA-approved ^[13]. It is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg given as a once-weekly injection. Novo Nordisk submitted its new drug application on December 18, 2025 based on the REDEFINE 1 trial, and FDA review is expected in 2026 ^[13].

In REDEFINE 1, at 68 weeks, weight loss was 22.7% with CagriSema versus 16.1% with semaglutide 2.4 mg, 11.8% with cagrilintide, and 2.3% with placebo ^[13]. In REDEFINE 4, announced February 23, 2026, CagriSema achieved 23% weight loss at 84 weeks but did not meet its primary endpoint of noninferiority against tirzepatide 15 mg. A phase 3 trial of a higher-dose 2.4 mg/7.2 mg combination is planned for the second half of 2026 ^[13].

When will Ozempic and Wegovy go generic in the US?

There is no FDA-approved generic version of Ozempic, according to a Drugs.com availability page updated August 13, 2026, which also warns that fraudulent online pharmacies may sell counterfeit products claimed to be generic Ozempic ^[14].

In the FDA Orange Book, the semaglutide compound patent 8,129,343 expires December 5, 2031, and a method-of-use patent 10,335,462 expires June 21, 2033, with later formulation patents running to 2038 and 2041 ^[14]. Novo Nordisk’s 2025 Form 20-F states that US compound patent protection for Ozempic, Rybelsus, and Wegovy runs to 2032, and discloses that several manufacturers filed abbreviated new drug applications with Paragraph IV certifications. Novo settled US Ozempic patent litigation with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy’s, Mylan, Zydus, and Apotex, with confidential terms ^[15]. Apotex holds the first FDA tentative approval for a generic semaglutide ANDA, granted in April 2026, which positions it to launch after Novo’s exclusivity and patents expire ^[16].

Why is generic semaglutide sold in Canada but not the US?

The difference traces to a lapsed Canadian patent. Novo Nordisk failed to pay a CAD 250 maintenance fee on Canadian patent CA 2601784, and the patent lapsed permanently ^[15]. Health Canada then approved Dr. Reddy’s generic semaglutide on April 28, 2026 and Apotex’s on May 1, 2026, both for the type 2 diabetes indication, with seven more submissions under review [15, 16]. Hims & Hers began offering the Apotex generic in Canada on May 21, 2026 as part of weight-loss plans starting at C$149 per month ^[17].

These Canadian approvals cover type 2 diabetes only, and they do not carry over to US pharmacies. In the US, Novo’s compound patent protection runs to 2032, so generic entry is expected years later ^[15].

What is the Medicare $50 GLP-1 Bridge?

CMS announced on May 6, 2026 that eligible Medicare Part D enrollees will be able to get certain GLP-1 medications for $50 per month under a time-limited demonstration running from July 1, 2026 through December 31, 2027 ^[18]. CMS describes the program as covering certain GLP-1 medications without naming the full list, and says it will share additional details as the program begins ^[18].

Lilly has stated that Foundayo is eligible for the $50 Medicare Part D price beginning as soon as July 1, 2026 ^[10].

Sources

1. Novo Nordisk. Ozempic (semaglutide) injection prescribing information.
2. Novo Nordisk. Wegovy (semaglutide) injection prescribing information.
3. Novo Nordisk. Ozempic (semaglutide) tablets prescribing information.
4. National Library of Medicine DailyMed. ZEPBOUND (tirzepatide) injection, solution.
5. National Library of Medicine DailyMed. MOUNJARO (tirzepatide) injection, solution.
6. National Library of Medicine DailyMed. FOUNDAYO (orforglipron) tablet, film coated.
7. National Library of Medicine DailyMed. TRULICITY (dulaglutide) injection, solution.
8. National Library of Medicine DailyMed. SAXENDA (liraglutide) injection, solution.
9. National Library of Medicine DailyMed. VICTOZA (liraglutide) injection.
10. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
11. UnitedHealthcare Provider Resources. Discontinuation of Bydureon BCise and Byetta. December 19, 2024.
12. Teva Pharmaceutical Industries. Teva announces FDA approval and launch of generic Saxenda (liraglutide injection), first generic GLP-1 indicated for weight loss.
13. Drugs.com. CagriSema (cagrilintide and semaglutide) FDA approval status. February 23, 2026.
14. Drugs.com. Generic Ozempic availability and release date. August 13, 2026.
15. Drug Discovery and Development. Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent.
16. Pearce IP. First generic Ozempic (semaglutide) approved in Canada for Dr Reddy’s & Apotex. April 29, 2026.
17. Reuters. Hims offers Apotex’s generic semaglutide in Canada after Novo patent expiry. May 21, 2026.
18. Centers for Medicare & Medicaid Services. Coming soon: CMS to provide $50 monthly access to GLP-1 medications for Medicare beneficiaries. May 6, 2026.
19. Pediatric Endocrine Society. New Meds and Tech: Mounjaro (tirzepatide) approved in pediatrics. February 24, 2026.